Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Oct 12, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for women with cervical cancer, specifically looking at a method called moderated hypofractionated online adaptive radiotherapy, combined with brachytherapy. The goal is to see if this treatment is safe and effective, especially since traditional radiation treatment can take a long time and strain medical resources. By participating in this trial, patients will receive a potentially shorter and more efficient treatment while being closely monitored for their safety and health outcomes.

To be eligible for this trial, participants must be women aged 18 to 75 who have been diagnosed with specific stages of cervical cancer. They should be able to tolerate lying flat for about half an hour and need to consent to the treatment plan. However, those who have had certain surgeries for cervical cancer or have other serious health conditions may not qualify. If eligible, participants can expect regular check-ups and support throughout their treatment as researchers gather valuable information to improve care for cervical cancer patients in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
• • 2. Age ≥18 and ≤75 years
• • 3. FIGO stage IB-IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
• • 4. Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• • 5. Concurrent weekly cisplatin therapy ± immunotherapy
• • 6. Able to undergo brachytherapy
• • 7. ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
• Exclusion Criteria:
• • 1. Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization
• • 2. FIGO stages IA, IIIC2, IVA, or IVB
• • 3. FIGO stage IIIC1 with lymph nodes \>2 cm, or with common iliac lymph node metastasis
• • 4. History of prior abdominal or pelvic radiotherapy
• • 5. Pregnant or breastfeeding women
• • 6. Patients with active infections or fever
• • 7. Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders.